ArticleAnnals of medicine and surgery (2012)2026
Prognostic impact of long-term beta-blockers post-stemi: a meta-analytic review.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This meta-analysis assessed the long-term impact of beta-blocker therapy on all-cause mortality and cardiovascular outcomes in patients with ST-elevation myocardial infarction (STEMI) who continued beta-blocker use for a minimum of 1 year after hospital discharge. Methods: Electronic databases were searched through September 2024 to identify studies comparing long-term outcomes in patients treated with beta-blockers versus those untreated. A random-effects model was used to estimate Hazard Ratios (HRs) with 95% confidence intervals (CIs). Results: A total of 21 studies involving 270 566 patients were included. In pooled analyses, extended beta-blocker was associated with significantly lower all-cause mortality in STEMI patients [HR: 0.74 (0.66, 0.83); Conclusion: Long-term beta-blocker use is associated with a significant reduction in all-cause mortality among STEMI patients, though this benefit was not seen in RCTs. Effects on other cardiovascular outcomes remain uncertain, highlighting the need for further large-scale trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.